TrialLipids in health and disease2021

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.

Maria C Foss-Freitas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.